P-126 Atezolizumab Plus Bevacizumab for Patients with Advanced Hepatocellular Carcinoma and Chronic Hepatitis B Virus Infection with High Viral Load

S. Chen,H. Lai,H. Tsou,Y. Shao,C. Chang,T. Su,T. Liu,L. Chen,A. Cheng,C. Hsu
DOI: https://doi.org/10.1016/j.annonc.2021.05.181
IF: 51.769
2021-01-01
Annals of Oncology
Abstract:Atezolizumab plus bevacizumab (A+B) is the current standard systemic therapy for patients with advanced hepatocellular carcinoma (HCC). This study sought to clarify its safety and efficacy in HCC patients who had chronic hepatitis B virus (HBV) infection and high viral load (NCT04180072). The first 10 subjects in the study constituted the safety run-in cohort. Eligible subjects must have histologically proven, locally advanced or metastatic and/or unresectable HCC that is not amenable to curative surgical and/or locoregional therapies, no prior systemic therapy for HCC, documented chronic HBV infection with HBV DNA > 2000 IU/mL within 28 days prior to initiation of study treatment, at least one measurable (per RECIST 1.1) lesion, ECOG score 0 or 1, and Child-Pugh class A. Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV was given every 3 weeks until documented tumor progression or unacceptable toxicity. Anti-HBV treatment was started prior to start of A+B treatment. The primary endpoint is overall response rate as per RECIST v1.1. Key safety endpoints (according to NCI CTCAE v5.0) included the proportion of subjects with ≥ grade 3 liver-related adverse events (AE), incidence and severity of all AE and immune-related AE, and incidence of HBV reactivation. From March 2020 to January 2021, 10 subjects were enrolled (men/women 10/0, median age 61.5 years, macrovascular invasion/ extra-hepatic metastasis 4/5, median alpha-fetoprotein 1722.16 ng/mL (range 2.25-80000)). Median HBV DNA levels at baseline were 35002.5 IU/mL (range 3350- 1760000). The median decrease of HBV DNA after A+B treatment (from baseline to the nadir level, in log scale) was 3.2 (range 0.7–5.1). No subjects had HBV reactivation, defined as either (1) HBV DNA increase ≧ 100 folds from baseline; (2) HBV DNA increase ≧ 10 folds from baseline and ≧ 3-fold increase in alanine aminotransferase (ALT); or (3) 2 consecutive increase in HBV DNA of ≧ 100 folds than previous nadir level. Grade 3 liver-related AE (transaminase elevation) occurred to 1 subject, who later confirmed partial response. The only other grade 3-4 treatment-related AE was hypertension (2 subjects). No subjects received steroid therapy for immune-related AE. As of February 2021, the subjects received a median of 6 cycles of A+B (range 2-14); 2 partial responses, 3 stable diseases, and 4 progressive diseases were documented in 9 evaluable subjects (1 subject with PD confirmed PR subsequently, suggesting pseudo-progression). A+B was safe for advanced HCC patients with high HBV viral loads at baseline. Recruitment was ongoing for better clarification of treatment efficacy and safety profile.
What problem does this paper attempt to address?